On December 18, 2024, Christina Rossi, the Chief Operating Officer of Blueprint Medicines Corp (BPMC, Financial), sold 2,274 shares of the company. Following this transaction, the insider now owns 69,383 shares of the company. The details of this transaction can be found in the SEC Filing.
Blueprint Medicines Corp (BPMC) is a precision therapy company focused on genomically defined cancers, rare diseases, and cancer immunotherapy. The company aims to improve the lives of patients with genomically defined diseases by creating new treatment paradigms.
Over the past year, Christina Rossi has sold a total of 10,618 shares and has not purchased any shares. The insider transaction history for Blueprint Medicines Corp shows that there have been no insider buys in total over the past year, while there have been 40 insider sells during the same period.
On the day of the recent sale, shares of Blueprint Medicines Corp were trading at $95.91, giving the stock a market cap of $5.726 billion. The stock's GF Value is estimated at $135.07, resulting in a price-to-GF-Value ratio of 0.71. This suggests that the stock is considered a "Possible Value Trap, Think Twice" based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on three factors:
- Historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
